BACkgRouNd: Proton pump inhibitors (PPIs) are among the highest expenditure drugs covered by health care plans. during fiscal year 2001-2002, Medicaid programs nationwide spent nearly $2 billion on PPIs. Although the costs of individual PPIs vary widely, there is little variation in therapeutic effectiveness. on June 1, 2007, the North Carolina Medicaid program implemented an "instant approval" option simultaneously with a prior authorization (PA) program for PPIs with the goal of managing costs and maintaining high-quality care. Preferred PPIs included generic omeprazole and Prilosec oTC. This instant approval process (IAP) was expected to impose less administrative burden than is typically associated with PA programs by permitting physician and nonphysician prescribers to either write the PA criteria directly on a prescription form or use "Md Easy," a preprinted form that could be faxed by the prescriber to the dispensing pharmacy. A previous study found that from the prescriber's perspective the IAP reduced practice-related administrative burden and was associated with a reduced gap in PPI therapy when compared with traditional PA.
• Traditional PA programs may be costly and burdensome to prescribers and pharmacists. Bukestein et al. (2006) found that physicians and nurses in an allergy practice averaged 1.9 and 5.6 phone calls per day, respectively, for PA, resulting in an average cost of $17.77 per PA. The specific costs of PA to pharmacies have not been identified in published literature.
• Alternatives to traditional PA, such as instant approval mechanisms, electronic PA, and web-based PA, are increasing and include the Missouri Medicaid automated electronic PA system (SmartPA) for cyclooxygenase-2 (COX-2) inhibitors, implemented in 2002, and a Medical Mutual of Ohio automated PA process (Smart Rules) for determining patient qualification for COX-2 inhibitors and antidepressants.
• Limited existing evidence suggests that alternative PA strategies may be effective and perceived as less burdensome to physicians than traditional PA. The automated electronic PA system in the Missouri Medicaid program was credited with reducing expenditures for COX-2 inhibitors by $131 per patient per year (PPPY) in 2003 compared with an increase of $59 PPPY in a comparison state without PA for COX-2 inhibitors.
• A previously published study of the North Carolina Medicaid instant approval process (IAP) for PPIs reported that the market share for preferred PPIs increased from 17% to 19% in the pre-IAP period to 76% in the first month after IAP implementation. Although market share changes were similar for practices using IAP and traditional PA, the median gap in PPI therapy for patients whose prescribers used traditional PA was approximately twice the gap for the IAP (26 days vs. 12 days, respectively, P < 0.001). Of the physician practices using IAP, 81.1% believed it reduced practice-related administrative burden.
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M edicaid expenditures for prescription drugs have increased over time at alarming rates. 1 After adjusting for inflation, total U.S. Medicaid expenditures for prescription drugs more than doubled from $11.6 billion to $23.7 billion from the fiscal years 1996-1997 to [2001] [2002] . 2 The North Carolina Medicaid program experienced an estimated 88% increase in prescription drug reimbursement between 2000 and 2005, from $795 million to $1.49 billion. 3 Between fiscal years 1996-1997 and 2001-2002 , similar trends in expenditure increases nationwide were observed for the broad class of drugs that treat gastrointestinal (GI) disorders. Medicaid expenditures nationwide for GI drugs increased from $1.02 billion in 1996-1997 to $1.83 billion in [2001] [2002] 2 driven in large part by proton pump inhibitors (PPIs). These increases were attributed to increases in the cost per user as well as growth in the number of people using GI drugs.
2
PPIs are a subclass of GI drugs that are indicated for shortterm therapy of acute upper GI disorders (e.g., peptic ulcers and esophagitis), pathologic gastric hypersecretory conditions (e.g., Zollinger-Ellison syndrome), and maintenance therapy for persons with healed ulcers and erosive esophagitis. [4] [5] [6] PPIs are among the costliest drugs covered by health care plans. 4 Although the costs of individual PPIs vary widely, there is little variation in therapeutic effectiveness among the PPIs. 6 State Medicaid programs and other payers have developed and implemented a number of strategies to attempt to curb rising prescription drug expenditures while ensuring appropriate access to prescription medications. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Existing evidence has shown that prior authorization (PA) is one approach that can be effective at reducing use of higher-cost medications when other equally effective and lower-cost alternatives are available. 4, 14, [17] [18] [19] [20] [21] [22] [23] PA has been defined as a process that "restricts the use of specific medications by requiring an advance approval by the Medicaid program or its agent for the drug before dispensing to qualify for reimbursement." 4 The benefit of PA to a payer is the ability to stop inappropriate utilization before it takes place. Although concerns about patient access exist, a number of published studies demonstrate safety and effectiveness of PA programs. 4, 14, 17, 20 Yet, studies of PA programs have not completely dispelled lingering criticisms. For example, high administrative costs are a major criticism of U.S. health care systems. [24] [25] [26] [27] In 1999, U.S. health care administrative costs were estimated at $294.3 billion or $1,059 per capita.
26 PA-related activities and other interactions between pharmacies, prescribers, and health insurance programs contribute to these administrative costs. 13, 24 Using data from a national survey, Casalino et al. (2009) estimated that the cost for the time spent by U.S. health care providers to interact with health insurance plans ranges from $23 to $31 billion annually. 24 They reported that the average amount of time spent weekly on authorizations was 13.1 hours by nursing staff for each physician in the practice, 1 hour per physician, and 6.3 hours for clerical staff. 24 Bukstein et al.
• This study builds on the previously published study of IAP for PPIs by focusing on the perceived administrative burden of traditional PA compared with IAP from the perspective of the pharmacist. Of responding pharmacists familiar with the IAP, 68.6% rated the IAP as being better or much better than traditional PA with respect to administrative burden to the pharmacy. Pharmacists reported that the IAP saved an estimated 21 work minutes per patient, on average, when compared with traditional PA.
• The use of a unique preprinted "MD Easy" PA form that could be faxed by prescribers to dispensing pharmacies was introduced despite concerns that the MD Easy form may make it easier to prescribe nonpreferred PPIs. However, in the first month after implementation of the IAP, the increase in preferred PPI market share was similar in practices using the MD Easy form and practices not using the MD Easy form (64.0 percentage points vs. 55.4 percentage points). In negative binomial regression modeling, the overall increase in preferred PPI market share after implementation of the IAP was 1.29 times higher for practices that used the MD Easy form than for those that did not; this difference approached statistical significance (95% CI = 1.00-1.68; P = 0.053).
• Of the pharmacies who rated the usefulness of the MD Easy form for expediting the PA form, most (95.5%) rated it good to excellent. Onethird of physician practices recalled receiving the MD Easy forms, and these practices reported that the MD Easy form helped to prevent gaps in therapy (92.9%) and follow PA requirements for PPI (100%).
What this study adds
What is already known about this subject (continued) dispense the drug without delay at the pharmacy. A previously published study assessed 2 objectives of the North Carolina Medicaid IAP for PPIs: (a) contain drug costs and (b) avoid clinical and service problems, such as gaps in therapy and clinician dissatisfaction. 31 The previous study reported that the market share for the preferred PPIs, generic omeprazole and Prilosec OTC, increased from 17% to 19% in the pre-IAP period to 76% in the first month after IAP implementation. 31 Although market share changes were similar for practices using the IAP and traditional PA, the median gap in PPI therapy for patients whose prescribers used traditional PA was approximately twice the gap for the IAP (26 days vs. 12 days, respectively, P < 0.001). Of the physician practices using IAP, 81.1% believed it reduced practice-related administrative burden.
The present study built on the previous study by including an assessment of the pharmacy experience and examining the use of pre-printed prescriptions. Specifically, the present study examined (a) pharmacist satisfaction with the IAP, (b) prescriber and pharmacist satisfaction with MD Easy, a preprinted prescription form, and (c) whether the rate of switching to preferred PPIs varied between those practices that used the MD Easy form compared with those practices that did not.
■■ Methods Description of the PA Intervention
Prior to June 2007, North Carolina Medicaid placed no coverage restrictions on PPIs. On June 1, 2007, North Carolina Division of Medical Assistance (DMA) implemented a PA program for PPIs for Medicaid beneficiaries. Out of concern for the potential burden that a PA program would place on prescribers and pharmacists, Community Care of North Carolina (CCNC), the state's Medicaid managed care program, requested that the PA process include an IAP as an alternative option to the traditional PA system. The new PA program included 3 options for patient access to PPIs. In option 1, prescriptions for the 2 preferred medications, generic omeprazole and Prilosec OTC, were exempt from PA. Option 2 was the traditional PA process for nonpreferred PPI medications. Option 3 included a unique IAP for nonpreferred PPIs that permitted prescribers to document the patient-specific approval criteria directly on the written prescription or use a pre-printed prescription form, MD Easy. Approval criteria for nonpreferred PPIs included (a) failure with a 30-day trial of no less than 40 milligrams (mg) of omeprazole during a 12-month period; (b) use of esomeprazole magnesium (Nexium) 40 mg for diagnosis of erosive esophagitis Grade C or D; or (c) inability to swallow tablets or capsules (use of brand name solutab and liquid dosage formulations). The PA policy excluded Medicaid beneficiaries who were aged 6 years or younger, those in an eligibility category indicating pregnancy, and dual eligible beneficiaries with Medicare Part D coverage.
As part of the IAP effort, CCNC created pre-printed (2006) found that the cost per PA of physician and nursing time within an allergy practice was $17.77. 28 Administrative costs of PA are also incurred by third-party payers. For example, one Medicaid program paid an administrative fee of $20 for each PA request for PPIs. 4 Less attention has been devoted to the administrative burden to pharmacies. Although pharmacists are not typically asked to submit written PA documentation to payers, they are nonetheless thrust into the middle of coverage determination activity. Traditional pharmacy PA typically involves a multistep process in which the physician or other prescriber writes a prescription, the patient takes the prescription to the local pharmacist, the prescription is denied through the electronic claims system, the pharmacist contacts the prescriber by telephone to indicate the need for PA, the prescriber contacts the PA center to initiate the PA, the prescription is approved or denied based on clinical criteria established by the payer, and potentially the prescriber notifies the pharmacy of the PA decision. If the pharmacy is not notified of the PA decision, the pharmacy may call the PA center to inquire about the status, periodically re-run the prescription in the electronic claims system to see if it is approved, or leave the process incomplete. Often acting as a messenger from patient to prescriber to payer and back, it is ultimately the pharmacist's responsibility to ensure that a drug is covered before dispensing it or risk denial of reimbursement for the dispensed prescription. In an era of multiple hundreds of prescriptions filled by a single pharmacist in a day, stopping the workflow to address a PA for a patient can be disruptive, even if the activity takes as little as 5 or 10 minutes to address with the patient and prescriber, mostly because of the sheer volume of PAs that a pharmacist may encounter on any given day.
Alternatives to traditional PA programs, including electronic PA and web-based PA, are beginning to emerge with the intent of improving administrative efficiency and reducing burden on providers, patients, and pharmacists while achieving costcontainment and quality of care goals. 17, 29, 30 However, limited empirical evidence exists on whether the alternative mechanisms actually achieve these administrative and cost-related goals. A study of a "SmartPA" system for cyclooxygenase-2 (COX-2) inhibitors in the Missouri Medicaid program, conducted by Carroll et al. (2006) , involved use of an automated electronic PA system that used clinical rules and queries of drug and medical claims data at the point of service. 17 This study reported reduced expenditures for COX-2 inhibitors as well as significant administrative cost avoidance over traditional PA based on a decrease in PA-related calls.
The instant approval process (IAP) is another alternative to traditional PA for managing access to specific types of prescription drugs. The IAP permits physician and nonphysician prescribers to document the patient-specific approval criteria directly on a written prescription so that the pharmacist can 
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MD Easy Form: Pre-Printed Prescription Form for Proton Pump Inhibitors
prescriptions, called MD Easy forms (Figure 1 ). Approximately 35,000 MD Easy forms were printed, 1 for each enrolled North Carolina Medicaid recipient who had a nonpreferred PPI claim during the previous year. The MD Easy forms were pre-populated with patient name, date of birth, address, prescribing practice, pharmacy, the nonpreferred drugs that the patient was currently taking, and instructions to select 1 of the 3 prescribing options. These forms were provided to each of the 14 CCNC networks to be sent to their respective primary care practices during May 2007. The new PA program with an IAP option and the deployment of MD Easy forms was intended to contain costs of PPIs, while maintaining high-quality care and reducing the administrative burden typically associated with traditional PA. The MD Easy form was also expected to facilitate patient access to a prescription through a preemptive PA process that occurs before the patient arrives at the pharmacy when picking up the next PPI refill.
Study Design and Participants
Cross-sectional and interrupted time series designs were used in this study. A cross-sectional design with a descriptive data analysis was used to assess pharmacist and prescriber satisfaction with the IAP and MD Easy form as alternatives to traditional PA for PPIs. A stratified simple random sample of 240 pharmacies was selected from 1,561 North Carolina pharmacies with claims in the North Carolina Medicaid claims data file during state fiscal year 2006 ( Figure 2 ). Random number generation was used in each stratum to select the final sample using SAS PROC SURvEYSELECT (SAS Institute Inc., Cary, NC). Pharmacies were stratified based on the number of unique Medicaid PPI pharmacy claims as a proxy measure for pharmacy size. Three strata were defined as (a) 10 or fewer PPI prescription claims (low volume, 80 of 704 pharmacies); (b) 11 to 49 PPI claims (medium volume, 80 of 757 pharmacies); and (c) 50 or more PPI claims (high volume, 80 of 100 pharmacies; Figure 2 ). Both rural and urban pharmacies were represented employees may be less likely to have the experience to compare traditional PA and IAP.
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A stratified simple random sample of 240 medical primary care practices was selected to participate in the PPI provider survey. These practices were selected from 1,045 primary care practices serving CCNC Medicaid beneficiaries with at least 1 PPI Medicaid claim during the state's fiscal year 2006 (Figure in the sample, based on a review of the distribution of RuralUrban Commuting Area (RUCA) scores for eligible pharmacies. 32 For each eligible pharmacy, 1 pharmacist was selected for interview or self-administered survey based on availability at the time of an on-site visit. Although there were no sampling exclusions, survey responses of 4 temporarily employed pharmacists were excluded from the survey results because these Completed survey n = 57 (71.3%)
FIGURE 3
Selection Prior to implementing data collection, 2 graduate pharmacy students completed interviewer training. In-person interviews were performed between mid-August and mid-December 2007 by these students at most pharmacy sites. For 7 pharmacies in more distant locations, regional CCNC network pharmacists performed the interviews, 6 in person and 1 by mailed questionnaire. Interviewers made initial contact in person at the eligible pharmacies and asked to conduct the brief structured interview at that time. If an interview could not be completed, a survey formatted for self-completion and a pre-addressed stamped survey return envelope were provided to the pharmacist. No attempts were made to re-contact nonresponding pharmacists. Interviewers assigned and documented unique study identification numbers on survey forms and master eligi- To construct the data file for the time series analysis, the FirstDataBank (FirstDataBank, San Francisco, CA) Specific Therapeutic Class (GC3) code "D4J" was used to select the pharmacy claims for PPI drug products. Physician survey responses were matched with calendar year 2007 pharmacy claims using CCNC practice identifier codes and Medicaid beneficiary primary care provider designations. The PPI claims were then assigned to 1 of 2 groups based on the practice survey results: (a) used the MD Easy form (i.e., reported using the IAP and receiving the MD Easy form [n = 56]) or (b) did not use the MD Easy form (n = 113, including 25 practices that answered "no" to the question "Did your practice receive any pre-populated MD Easy forms?" and 88 practices that either reported not using the IAP [n = 84] or reported using the IAP but did not reply to the question about receipt of the MD Easy forms [n = 4]). Preferred PPI market share was computed for each of the 2 groups for each month as the number of preferred PPI prescription claims divided by the total number of preferred and nonpreferred PPI prescription claims. The preferred market share percentages were plotted for 12 sequential months for calendar year 2007 separately for those practices Market Share of Preferred PPI Prescriptions. An interrupted time series analysis was used to assess overall pre-post changes in preferred PPI market share and compare practices that used the MD Easy form with those that did not, assessing (a) market share of preferred PPIs prior to implementing the IAP and (b) change in market share of preferred PPIs (percent of total) after implementation of the IAP. Market share data were analyzed within a log negative binomial regression model to account for the autocorrelation in the time series data. These tests were implemented using PROC GENMOD in SAS. 33 Question (a) was tested using 5 months of market share data immediately prior to IAP implementation. Question (b) was tested using the full 12 months of market share data.
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■■ Results Pharmacist Satisfaction with IAP for PPIs
The pharmacy survey was completed by 202 of 240 (84.2%) Physician practice survey results (continued) n (%) n (%) n (%) n (%)
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TABLE 1
Pharmacist and Physician Satisfaction with the PPI Instant Approval Process and the MD Easy Form (continued)
traditional PA for pharmacy benefits. The results of this study suggest that an IAP for prescription medications may be more administratively efficient for pharmacists than traditional PA processes while retaining the desired channeling effects. More than two-thirds of pharmacists in this study reported that the IAP was administratively less burdensome than traditional PA. This finding was consistent with the expectations and intent of investigators. The channeling to preferred PPI medications was similarly effective for practices that used the MD Easy form compared with those not using the MD Easy form. This finding was somewhat unexpected; the MD Easy form may make it easier for physicians to prescribe nonpreferred PPIs because the specific exemption criteria are listed directly on the form. One possible explanation for this result is the potential for a null effect of a barrier on prescribers' decision-making processes. That is, the level of difficulty of the PA override process may not affect the switching decision because patients who meet criteria or insist on using the nonpreferred medication receiving the pre-populated MD Easy forms, 92.9% reported that these forms very much or somewhat helped prevent gaps in therapy or days of missed therapy for their patients receiving PPIs. The MD Easy forms also were reported to very much or somewhat help 98.2% of responding practices identify patients affected by Medicaid PPI PA, and 100% of respondents reported that the information on the forms very much or somewhat helped them to follow requirements for PPI PA. Almost all of the practices (98.2%) rated the MD Easy forms as somewhat to extremely useful (Table 1) . Survey results did not vary significantly among the strata of physician practices. Table 2 ). The increase in preferred market share between May and June was an absolute 64.0% (from 19.3% to 83.3%, P < 0.001) for practices using the MD Easy form and an absolute 55.4% (from 21.8% to 77.2%, P < 0.001) for practices not using the MD Easy form (Figure 4) . The pre-IAP baseline market share of preferred PPIs in the group of practices that did not use the MD Easy form was 1.24 (95% CI = 1.10-1.40) times as high or approximately 4 percentage points higher compared with the practices that used the MD Easy form (P < 0.001). The overall increase in preferred PPI market share after implementation of the IAP was 1.29 times higher in the group that used the MD Easy form than the group of practices that did not; this difference approached statistical significance (95% CI = 1.00-1.68; P = 0.053).
Market Share of Preferred PPI Prescriptions
■■ Discussion
The trend to shift pharmacy management strategies from traditional PA programs to alternative strategies such as instant approval, electronic PA, and web-based PA is growing. Traditional PA programs have an established history of successfully moving market share to preferred drug products and limiting utilization of nonpreferred products. The downside to PA programs to date has been patient, prescriber, and pharmacy dissatisfaction, specifically the administrative costs of filling out paperwork, phoning, and faxing, as well as increased time between fills for patients seeking a medication that has a PA without immediate resolution. Third-party payers in Tennessee and New Jersey announced plans in early 2009 to launch a pilot electronic PA program. 34 Moreover, the American Medical Association's House of Delegates, at its June 2008 annual meeting, adopted a policy to support legislative efforts to mandate less administratively burdensome and costly pharmacy management strategies. 35 The current evaluation of the North Carolina Medicaid IAP for PPIs provides evidence to support the shift away from 
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for practices using traditional PA and IAP, the median gap in PPI therapy for patients whose prescribers used traditional PA was approximately twice the gap with the IAP (26 vs. 12 days, respectively, P < 0.001). And, of the physician practices using IAP, 81.1% believed it reduced practice-related administrative burden. The present study is the first report of which we are aware to focus on PA-related pharmacy burden and use of a pre-printed prescription form.
The North Carolina Medicaid PPI PA program had the advantage of the 14 CCNC networks, its pharmacists, and regular medical management meetings to educate providers and support the effort. 36 The ability to call on pharmacies and practices in person with existing human resources that already had established relationships was advantageous both for implementation and evaluation. One of the few drawbacks to the program was its limited scope with respect to a single drug class from a single payer. While pharmacists generally gave positive feedback about the IAP approach, it would likely be advantageous to patients, prescribers, and pharmacies if consistent phraseology for pharmacy claim PA override or procedures that cut across all drug classes and payers were developed. A more efficient IAP drug management program may be created through collaboration with other state Medicaid may ultimately receive the PA override, however difficult or easy to attain.
The results of this study are consistent with a limited body of published peer-reviewed literature on evaluations of automated or instant approval pharmaceutical PA programs. The evaluation of an automated PA system for COX-2 inhibitors in the Missouri Medicaid program demonstrated a shift in use of COX-2 inhibitors to less costly nonsteroidal anti-inflammatory drugs (NSAIDs). 17 The automated PA system was credited with reducing expenditures for COX-2 inhibitors by $131 per patient per year (PPPY) compared with an increase of $59 PPPY in a comparison group without PA for COX-2 inhibitors. 17 In addition, it was estimated that administrative costs were reduced by $150,000 to $925,000 per year based on an estimated drop in PA call center volume by 15,000 to 37,000 telephone calls per year at an estimated cost of $10 to $25 per PA request.
17
A previously published study of the North Carolina Medicaid IAP for PPIs reported that the average monthly PPI drug costs dropped from approximately $4 million to approximately $1.5 million immediately after implementation of the PA program. 31 The market share for preferred PPIs increased from 17% to 19% in the pre-IAP period to 76% in the first month after IAP implementation. 31 Although market share changes were similar 
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on pharmacist availability. It is possible that experiences of those not surveyed may differ from those of survey respondents. An attempt was made to obtain the most informed respondents by requesting participation of the physician in each practice with the most experience with the IAP for PPIs. Yet, self-selection is likely to have occurred to some extent within each physician practice. Third, many of the survey items asked the respondents to make relative comparisons to previous PA experiences. Prior to this PA program, the North Carolina Medicaid program had nearly complete open access, without a preferred drug list or any substantially disruptive PA policies affecting large numbers of prescribers or patients. It is possible that the addition of any PA requirement, even one that involves an IAP, may tend to bias the responses in the direction of understating satisfaction because historically North Carolina Medicaid has adopted less aggressive PA policies affecting small numbers of enrollees. However, given the widespread use of PA programs across payers, this potential source of bias is unlikely.
Fourth, the use of an interrupted time-series design for studying the effect of introducing a PA policy was a natural experiment without a comparison group and is not a strong design for controlling for threats to internal or external validity. The dramatic increase in the prescribing of preferred PPIs after the PA policy implementation could potentially be attributed to other factors. For example, physicians may be more likely to adhere to the PA policy when they are aware of being observed in an investigation. The sustainability of market share results over 7 months reduces this concern because physicians were directly involved in the study for only a brief time period, the time to complete a survey. Another potential explanation for successful channeling to preferred PPIs may be the involvement of early adopters or highly performing physicians in the study. Given that the PPI prescribing patterns were summarized for responding practices rather than individual responding physicians, this concern is unlikely to represent a major threat to study validity.
■■ Conclusion
This study provides evidence that an IAP for PPIs is an effective alternative to traditional PA approaches for prescription drugs. The method, including use of the MD Easy form, was associated with an increase in market share of preferred PPIs and was reported to be less administratively burdensome to pharmacists than traditional PA. Additional studies are needed to determine sustainability and applicability to other prescription drugs.
programs and private payers, using universal override procedures and criteria.
The use of IAP can be applied across many drug classes and drug product types. A program similar to the PPI IAP has been in place in North Carolina Medicaid for palivizumab since 2004. Palivizumab is a humanized monoclonal antibody that has been shown to reduce the occurrence of respiratory syncytial virus-related hospitalizations in high-risk infants. 37 Within North Carolina Medicaid, generally only the specialty pharmacies have participated in dispensing palivizumab. 37 Palivizumab is both expensive and more time sensitive for administration than most other drug products, necessitating a PA program that is "user friendly" for patients, prescribers, and pharmacies. Although palivizumab requires PA in North Carolina, pharmacies can dispense the medication and be guaranteed reimbursement based on criteria and paperwork that can be submitted retroactively, allowing for the immediate delivery and administration of the drug product.
38
Unlike IAP for PPIs, use of MD Easy forms may not be feasible for all types of drug products. For the PPI program, there were logical and evidence-based therapeutic alternatives to nonpreferred products that provided prescribers an alternative to seeking an override. When the MD Easy form acts as a prescription for an alternative product, it allows the practice to quickly make switching and IAP decisions for all of its patients who would be affected by the PA prior to the policy taking effect. For PA policies other than therapeutic interchanges, such as limits on total daily dose, unit counts over time, or restrictions based on diagnosis with no "step therapy" or "fail first" component, the MD Easy form may act primarily as an educational tool or care alert because no new prescriptions for an alternative medication are expected.
Limitations
First, the IAP and the MD Easy form were compared with traditional PA using measurements of perceived burden. The actual administrative time and costs of each approach were not measured using direct observations and time studies. However, the perceived burden and relative acceptability of the PA approach are important considerations in efforts intended to reduce barriers to adoption of innovations.
Second, although the response rates to both the pharmacy (84.2%) and physician (71.3%) surveys were relatively high, only about one-third of responding physicians and two-thirds of responding pharmacists reported having had experience with IAP or the MD Easy form, thus limiting the sample size for this study. In addition, the survey results may be influenced by selection bias because only 1 pharmacist or physician was surveyed on behalf of each pharmacy or medical practice, and the pharmacist interviews were conducted based
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